<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00438581</url>
  </required_header>
  <id_info>
    <org_study_id>BMA-05-017-ZEV</org_study_id>
    <nct_id>NCT00438581</nct_id>
  </id_info>
  <brief_title>Study Combining Zevalin With High-Dose Chemotherapy Prior to Autologous StemCell Transplant in Patients With Relapsed, Refractory, or Transformed Non-Hodgkin's Lymphoma</brief_title>
  <acronym>Zevalin</acronym>
  <official_title>Phase II Non-Randomized Study Combining Yttrium 90 Ibritumomab Tiuxetan (Zevalin) With High-Dose Chemotherapy Prior to Autologous Stem Cell Transplantation in Patients With Relapsed, Refractory, or Transformed Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>McGill University Health Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McGill University</source>
  <brief_summary>
    <textblock>
      This aim of this study to evaluate the safety and efficacy of combining a single course of
      Yttrium 90 Ibritumomab Tiuxetan, a radiolabeled monoclonal antibody ( Zevalin ), with
      high-dose BEAM chemotherapy and autologous peripheral stem cell transplantation in patients
      with relapsed, refractory, or transformed Non-Hodgkin's lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Relapse rates after chemotherapy for relapsed, refractory or transformed Non-Hodgkin's
      lymphoma (NHL)remain very high. NHL is a radiosensitive tumor. We hypothesize that targeted
      radioimmunotherapy combined with high-dose chemotherapy may increase response and survival
      rates in a safe and reliable manner.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2007</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival Data, adverse events, molecular response</measure>
  </secondary_outcome>
  <enrollment>40</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Yttrium 90 Ibritumomab Tiuxetan ( Zevalin )</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt;=18 to &lt;=70 years

          2. Relapsed or refractory Stage III or IV, grade 1,2, or 3 Follicular Lymphoma or
             transformed follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma,
             Waldenstrom's macroglobulinemia, or diffuse large B-Cell lymphoma as defined by the
             WHO and:

               -  Expressing the CD 20 antigen

               -  ECOG performance 0-2

               -  Written informed consent

          3. Prior collection of at least 2.5x10^6 CD34-positive peripheral blood stem cells/kg.

        Exclusion Criteria:

          1. Abnormal renal function (Creatinine &gt;2.5x upper limit of normal (ULN)

          2. Abnormal hepatic function (Bilirubin &gt;2xULN, ALT/AST &gt;3x ULN)

          3. Cardiac ejection fraction &lt;40%

          4. Severe defects in pulmonary function tests (DLCO&lt;70% predicted, FEV1, FVC&lt;60%
             predicted) or receiving continuous oxygen

          5. A history of human anti-mouse antibodies (HAMA) or known type 1 hypersensitivity or
             anaphylactic proteins to any component of the Zevalin therapy.

          6. Female patients who are pregnant or breast feeding, and adults of reproductive
             potential who are not employing an effective method of birth control during study
             treatment

          7. Prior radiotherapy to &gt;25% of the bone marrow or &gt;20 Gy to critical organ (lung,
             liver, kidney, spinal cord).

          8. CNS lymphoma

          9. Ongoing infection

         10. Prior treatment with radioimmunotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Galal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University Health Center, Royal Victoria Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed Galal, MD</last_name>
    <phone>514-934-1934</phone>
    <phone_ext>31558</phone_ext>
    <email>galala@muhchem.mcgill.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>McGill University Health Center, Royal Victoria Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ahmed Galal, MD</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>31558</phone_ext>
      <email>galala@muhchem.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Ahmed Galal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2007</study_first_submitted>
  <study_first_submitted_qc>February 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2007</study_first_posted>
  <last_update_submitted>February 26, 2007</last_update_submitted>
  <last_update_submitted_qc>February 26, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2007</last_update_posted>
  <keyword>Zevalin</keyword>
  <keyword>Autologous one Marrow Transplant</keyword>
  <keyword>Non-Hodgkin's Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

